Urticarial vasculitis - Vasculitis Urticarial
☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
References
Is riocht annamh é Urticarial vasculitis marcáilte ag eipeasóidí fada buana nó athfhillteacha coirceoga. Cé gur féidir le hairíonna a chraicinn a bheith cosúil le coirceoga ainsealacha, tá siad uathúil mar go gcaitheann na coirceoga thart ar feadh 24 uair an chloig ar a laghad agus go mbíonn siad ina gcúis le spotaí dorcha nuair a bhíonn siad fadaithe. Cé gur cúis anaithnid é go minic, uaireanta féadann cógais áirithe, ionfhabhtuithe, galair uath-imdhíonachta, neamhoird fola nó ailsí é a spreagadh. Cheangail roinnt staidéir é le fliú COVID-19 agus H1N1 fiú. Is féidir leis tionchar a bheith aige freisin ar chodanna eile den chorp mar na matáin, na duáin, na scamhóga, na boilg agus na súile. Cé gur féidir le cineál áirithe scrúdú fíocháin an diagnóis a dhearbhú, ní gá i gcónaí. Tosaíonn cóireáil de ghnáth le antaibheathaigh, dapsone, colchicine, nó hidroxychloroquine i gcásanna níos séimhe. I gcás cásanna níos déine, d'fhéadfadh go mbeadh gá le drugaí a shochtann an córas imdhíonachta cosúil le methotrexate nó corticosteroidí. Le déanaí, léirigh teiripí bitheolaíocha (rituximab, omalizumab, interleukin-1 inhibitors) gealltanas do chásanna diana.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Tháinig fear 35 bliain d'aois isteach le stair 15 lá de ghríosa geala dearga, pianmhara ar an dá thigh agus ar na cosa, chomh maith le pian sa chomhpháirteach. Bhí ionfhabhtú sa chonair urinary air ar feadh seachtaine sular tháinig an gríos. Thaispeáin a chraiceann roinnt plaiceanna dearga tairisceana, fáinne-chruthacha, a raibh cuid de blanchable orthu, ar an dá thaobh dá thighs agus dá chosa. Tugadh prednisolone béil (40mg in aghaidh an lae) dó ar feadh seachtaine mar aon le frithhistamine neamh-codarach (fexofenadine) . Laistigh de sheachtain, imithe na rashes go léir go hiomlán. Ní raibh a thuilleadh gríosa ann le linn na chéad 6 mhí eile de sheiceálacha rialta.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
○ Cóireáil - Drugaí OTC
Má tá fiabhras ort (teocht an choirp méadaithe), molaimid duit aire leighis a lorg a luaithe is féidir.
Ba cheart an druga amhrasta a scor. (m.sh. antaibheathaigh, drugaí frith-athlastach neamhstéaróideach)
Frithhistamíní ó bhéal mar cetirizine nó loratadine le haghaidh itching.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]
D’fhéadfadh ointments steroid thar an gcuntar a bheith neamhéifeachtach le haghaidh an potency íseal. Ní mór é a chur i bhfeidhm ar feadh níos mó ná seachtain chun feabhas a fheiceáil.
#Hydrocortisone ointment